Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
[Results of adjuvant chemotherapy (XELOX) of advanced colorectal cancer].
[papillon-lefèvre syndrome]
While
the
most
frequent
,
surgery
for
colorectal
cancer
is
avoided
in
patients
with
metastases
to
the
regional
lymph
nodes
(
stage
III
)
or
distant
ones
(
stage
IV
)
.
Hence
,
it
is
being
increasingly
substituted
with
neoadjuvant
treatment
.
Our
investigation
is
concerned
with
prospective
evaluation
of
the
efficacy
and
toxicity
profile
of
capecitabine
(
XELODA
)
in
combination
with
oxaliplatin
(
XELOX
)
and
adjuvant
Mayo
treatment
(
stage
IIb-
III
)
.
Patients
had
undergone
radical
surgery
(
somatic
status
<
or
=
2
-
ECOG
)
.
The
prospective
group
(
166
)
received
8
courses
of
adjuvant
polychemotherapy
(
XELOX
)
;
the
retrospective
(
2001
-
2005
)
one
(
152
)
-
-
6
(
Mayo
)
.
The
groups
matched
one
another
as
far
as
number
,
gender
,
age
and
primary
tumor
localization
are
concerned
.
Regional
lymph
node
involvement
in
group
1
was
64
.
5
%
;
group
2
-
-
59
.
8
%
.
Lympho-
vascular
invasion
by
tumor
was
typical
of
group
1
;
gastrointestinal
toxicity
-
9
.
2
%
(
Mayo
)
vs
.
7
.
2
%
in
group
1
.
Hematological
complications
were
5
.
4
%
(
XELOX
)
and
5
.
3
%
(
Mayo
)
;
neutropenia
--
5
.
0
%
(
Mayo
)
and
3
.
0
%
(
XELOX
)
;
polyneutropenia--
3
.
6
%
(
XELOX
)
;
capecitabine-related
Papillon-
Lefevre
syndrome--
8
.
4
%
.
Three
-
year
relapse-free
survival
was
53
.
0
%
(
XELOX
)
and
47
.
5
%
(
Mayo
)
.
After
adjuvant
treatment
,
toxicity
profile
with
XELOX
was
lower
than
that
after
Mayo
,
with
the
survival
tending
to
improve
.
